152 related articles for article (PubMed ID: 11597543)
1. Effective long-term androgen suppression in men with prostate cancer using a hydrogel implant with the GnRH agonist histrelin.
Schlegel PN; Kuzma P; Frick J; Farkas A; Gomahr A; Spitz I; Chertin B; Mack D; Jungwirth A; King P; Nash H; Bardin CW; Moo-Young A
Urology; 2001 Oct; 58(4):578-82. PubMed ID: 11597543
[TBL] [Abstract][Full Text] [Related]
2. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer.
Chertin B; Spitz IM; Lindenberg T; Algur N; Zer T; Kuzma P; Young AJ; Catane R; Farkas A
J Urol; 2000 Mar; 163(3):838-44. PubMed ID: 10687989
[TBL] [Abstract][Full Text] [Related]
3. An evaluation of the pharmacokinetics and pharmacodynamics of the histrelin implant for the palliative treatment of prostate cancer.
Dineen MK; Tierney DS; Kuzma P; Pentikis HS
J Clin Pharmacol; 2005 Nov; 45(11):1245-9. PubMed ID: 16239357
[TBL] [Abstract][Full Text] [Related]
4. Reversibility of androgen deprivation therapy in patients with prostate cancer.
Fridmans A; Chertin B; Koulikov D; Lindenberg T; Gelber H; Leiter C; Farkas A; Spitz IM
J Urol; 2005 Mar; 173(3):784-9. PubMed ID: 15711270
[TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy and tolerability of once-yearly histrelin acetate subcutaneous implant in patients with advanced prostate cancer.
Shore N; Cookson MS; Gittelman MC
BJU Int; 2012 Jan; 109(2):226-32. PubMed ID: 21851539
[TBL] [Abstract][Full Text] [Related]
6. Histrelin: in advanced prostate cancer.
Deeks ED
Drugs; 2010 Mar; 70(5):623-30. PubMed ID: 20329807
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of histrelin subdermal implant in patients with advanced prostate cancer.
Schlegel PN;
J Urol; 2006 Apr; 175(4):1353-8. PubMed ID: 16515997
[TBL] [Abstract][Full Text] [Related]
8. Relationships between FSH, inhibin B, anti-Mullerian hormone, and testosterone during long-term treatment with the GnRH-agonist histrelin in patients with prostate cancer.
Eldar-Geva T; Liberty G; Chertin B; Fridmans A; Farkas A; Margalioth EJ; Spitz IM
Eur J Endocrinol; 2010 Jan; 162(1):177-81. PubMed ID: 19820037
[TBL] [Abstract][Full Text] [Related]
9. Histrelin Hydrogel Implant--Valera: Histrelin implant, LHRH-Hydrogel implant, RL 0903, SPD 424.
Drugs R D; 2005; 6(1):53-5. PubMed ID: 15801868
[TBL] [Abstract][Full Text] [Related]
10. The histrelin implant: a novel treatment for central precocious puberty.
Hirsch HJ; Gillis D; Strich D; Chertin B; Farkas A; Lindenberg T; Gelber H; Spitz IM
Pediatrics; 2005 Dec; 116(6):e798-802. PubMed ID: 16322137
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial.
Eugster EA; Clarke W; Kletter GB; Lee PA; Neely EK; Reiter EO; Saenger P; Shulman D; Silverman L; Flood L; Gray W; Tierney D
J Clin Endocrinol Metab; 2007 May; 92(5):1697-704. PubMed ID: 17327379
[TBL] [Abstract][Full Text] [Related]
12. Analysis of testosterone suppression in men receiving histrelin, a novel GnRH agonist for the treatment of prostate cancer.
Djavan B; Schlegel P; Salomon G; Eckersberger E; Sadri H; Graefen M
Can J Urol; 2010 Aug; 17(4):5265-71. PubMed ID: 20735905
[TBL] [Abstract][Full Text] [Related]
13. Long-acting gonadotropin-releasing hormone implant to maintain medical castration for two years in men with prostate cancer.
Spitz IM; Chertin B; Lindenberg T; Farkas A
N Engl J Med; 1999 May; 340(18):1439. PubMed ID: 10328706
[No Abstract] [Full Text] [Related]
14. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
Kobayashi T; Nishizawa K; Mitsumori K
Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
[TBL] [Abstract][Full Text] [Related]
15. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
Pathak AS; Pacificar JS; Shapiro CE; Williams SG
J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
[TBL] [Abstract][Full Text] [Related]
16. Duration of testosterone suppression after a 9.45 mg implant of the GnRH-analogue buserelin in patients with localised carcinoma of the prostate a 12-month follow-up study.
Pettersson B; Varenhorst E; Petas A; Sandow J
Eur Urol; 2006 Sep; 50(3):483-9. PubMed ID: 16626856
[TBL] [Abstract][Full Text] [Related]
17. Gonadotrophin and testosterone suppression by 7alpha-methyl-19-nortestosterone acetate administered by subdermal implant to healthy men.
Noé G; Suvisaari J; Martin C; Moo-Young AJ; Sundaram K; Saleh SI; Quintero E; Croxatto HB; Lähteenmäki P
Hum Reprod; 1999 Sep; 14(9):2200-6. PubMed ID: 10469681
[TBL] [Abstract][Full Text] [Related]
18. Hormonal therapy for patients with advanced adenocarcinoma of the prostate: is there a role for discontinuing treatment after prolonged androgen suppression?
Pedraza R; Kwart AM
Urology; 2003 Apr; 61(4):770-3. PubMed ID: 12670563
[TBL] [Abstract][Full Text] [Related]
19. Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders.
Behre HM; Baus S; Kliesch S; Keck C; Simoni M; Nieschlag E
J Clin Endocrinol Metab; 1995 Aug; 80(8):2394-403. PubMed ID: 7543113
[TBL] [Abstract][Full Text] [Related]
20. A review of the pharmacokinetic and pharmacological properties of a once-yearly administered histrelin acetate implant in the treatment of prostate cancer.
Schlegel P
BJU Int; 2009 Mar; 103 Suppl 2():7-13. PubMed ID: 19228147
[No Abstract] [Full Text] [Related]
[Next] [New Search]
